Yoav Shaked
DarioHealthAbout Yoav Shaked
Yoav Shaked, age 53, is an independent director and Chairman of the Board of DarioHealth, serving as Chair since July 5, 2018; he holds a B.A. in biology from The Hebrew University of Jerusalem and brings deep biotechnology and venture capital experience . He co-founded Medpoint Ltd. (2005), founded and led Y-Med Inc. (sold to C.R. Bard in 2009), and later served as director of research at ThermopeutiX; since 2011 he has been a partner at Sequoia Capital .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Y-Med Inc. | Founder & Chief Executive Officer; led sale to C.R. Bard, Inc. | May 2004 – Nov 2009 | Built and exited a medical device company |
| ThermopeutiX | Director of Research | Post-2009 (after Y-Med sale) | Product development in stroke and PAD devices |
| Medpoint Ltd. | Co-founder (medical device distribution) | 2005 – (unspecified) | Distribution of medical products |
| Sequoia Capital | Partner | Since 2011 | Venture investing expertise |
External Roles
| Organization | Role | Tenure/Status | Notes |
|---|---|---|---|
| Orasis Pharmaceuticals, Ltd. | Chairman of the Board | Current | Biotech; chair role |
| Endospan Ltd. | Director | Current | Biotech |
| Vibrant Ltd. | Director | Current | Biotech |
| G&G Biotechnology Ltd. | Director | Current | Biotech |
| Sequoia Capital | Partner | Since 2011 | VC firm |
Board Governance
- Independence: The Board determined Shaked is an “independent director” under Nasdaq and Rule 10A‑3 .
- Board attendance: Board met telephonically 8 times in FY2024 and acted by unanimous written consent 8 times; each director attended at least 88% of meetings .
- Committee memberships and engagement:
- Audit Committee: Members Shaked, McGrath (Chair), Matheis; met 4 times and acted by unanimous written consent on 8 occasions; 100% attendance by members .
- Compensation Committee: Members Shaked, McGrath (Chair), Karah; met 1 time and acted by unanimous written consent on 14 occasions .
- Nominating & Corporate Governance Committee: Members Shaked and Matheis (Chair); acted by unanimous written consent on 1 occasion in FY2024 .
| Committee | Members | Chair | FY2024 Meetings | FY2024 UWC Actions | Attendance |
|---|---|---|---|---|---|
| Audit | Shaked, McGrath, Matheis | McGrath | 4 | 8 | 100% by members |
| Compensation | Shaked, McGrath, Karah | McGrath | 1 | 14 | Not individually disclosed (committee engagement high) |
| Nominating & Corporate Governance | Shaked, Matheis | Matheis | 0 (UWC used) | 1 | Not individually disclosed |
Fixed Compensation
| Component | Policy/Amount | Actual FY2024 Paid |
|---|---|---|
| Annual cash retainer | $50,000/year (paid quarterly) | $17,500 (partial year before cash waiver) |
| Committee service fee | $20,000/year (paid quarterly) | Included in cash until waiver; exact split not disclosed |
| Cash waiver | Shaked waived cash compensation beginning Q2 2024 | Effective Q2 2024 |
Performance Compensation
| Grant Type | Grant Date | Shares/Options | Strike/Exercise | Grant-Date Fair Value | Vesting |
|---|---|---|---|---|---|
| Restricted shares (Stock Award) | March 6, 2024 | 90,000 restricted shares | N/A | $151,200 | Not disclosed in proxy |
| Options | N/A in FY2024 | None outstanding as of 12/31/2024 | N/A | N/A | N/A (10) |
| Performance Metrics in Director Compensation | Disclosure |
|---|---|
| Metrics tied to director equity/cash | None specified; director equity awards described as restricted shares without stated performance conditions |
Other Directorships & Interlocks
| Company | Role | Committee Roles (elsewhere) | Potential Interlocks with DRIO |
|---|---|---|---|
| Orasis Pharmaceuticals, Ltd. | Chairman | Not disclosed | None disclosed |
| Endospan Ltd.; Vibrant Ltd.; G&G Biotechnology Ltd. | Director | Not disclosed | None disclosed |
- Related-party transactions: Proxy discloses an external consulting arrangement with NearWater Growth LLC related to director Lawrence Leisure; no similar arrangements are disclosed for Shaked .
Expertise & Qualifications
- Biotechnology operator and entrepreneur (founder/CEO Y‑Med; director of research at ThermopeutiX) .
- Venture capital experience as partner at Sequoia Capital since 2011 .
- Academic credentials: B.A. in biology (Hebrew University of Jerusalem) .
Equity Ownership
| Item | Amount | Notes |
|---|---|---|
| Beneficial ownership (May 29, 2025) | 260,657 shares | Less than 1% of outstanding; includes spouse’s 1,667 shares; includes 155,359 vested restricted shares |
| Percent of shares outstanding | * <1% | Based on 44,463,781 shares outstanding |
| Vested vs unvested | 155,359 vested restricted shares included; unvested not itemized | Per footnote (9) |
| Options (exercisable/unexercisable) | None outstanding as of 12/31/2024 | Per summary table footnote (10) |
| Stock awards outstanding (12/31/2024) | 253,896 stock awards | Outstanding stock awards balance (9) |
| Shares pledged as collateral | Not disclosed | — |
Governance Assessment
- Alignment and engagement: Independent Chairman with active committee participation (member of all three standing committees) and documented committee-level 100% attendance in Audit, and high engagement through unanimous written consents across committees . Waiver of cash fees beginning Q2 2024 suggests cash preservation and equity alignment during the period .
- Compensation mix: Director pay tilted to equity via restricted shares (90,000 shares granted in March 2024; fair value $151,200) and minimal cash due to waiver; no options outstanding as of year-end 2024, indicating lower risk equity structure .
- Ownership: Beneficial ownership is modest (<1%) but includes meaningful vested restricted shares; no pledging disclosed; options absent as of 12/31/2024 .
- Independence and committees: Formally determined independent; sits on Audit, Compensation, and Nominating & Corporate Governance committees without chairing them, while serving as non-executive Chairman of the Board .
- Potential conflicts: No related-party transactions disclosed for Shaked; the only director-related consulting arrangement disclosed pertains to another director (Leisure/NearWater) .
- Investor sensitivity context: The 2025 proxy includes proposals to authorize a reverse split and increase authorized shares, which the Board noted could have anti-takeover effects under certain circumstances; while not specific to Shaked, investors should monitor board actions under his chairmanship for capital structure changes .